TNF and rheumatoid arthritis: In summary, decreased serum levels of sVCAM-1, MCP-1 and ADMA after successful anti-TNF-α therapy may indicate reduced endothelial activation/dysfunction, mainly by achieving inflammation control, which is an important mechanism for preventing the development of cardiovascular events in RA patients.